Physicians - maximum of 0.25 AMA PRA Category 1 Credit(s)™
ABIM Diplomates - maximum of 0.25 ABIM MOC points
Nurses - 0.25 ANCC Contact Hour(s) (0 contact hours are in the area of pharmacology)
Pharmacists - 0.25 Knowledge-based ACPE (0.025 CEUs)
Physician Assistant - 0.25 AAPA hour(s) of Category I credit
IPCE - 0.25 Interprofessional Continuing Education (IPCE) credit
This activity is intended for pediatricians, internists, family medicine and primary care clinicians, pharmacists, nurses, neurologists, allergists and clinical immunologists, physician assistants, adolescent medicine clinicians, and other members of the health care team for patients with childhood allergies who may be at risk for attention-deficit/hyperactivity disorder and autism spectrum disorder.
The goal of this activity is for learners to be better able to describe the association of allergic disorders with attention-deficit/hyperactivity disorder and autism spectrum disorder in a large cohort of pediatric patients (0-18 years), based on a retrospective study using the pediatric database (International Classification of Diseases, 9th revision, Clinical Modification codes) of Clalit Health Services during 2000 to 2018.
Upon completion of this activity, participants will:
Medscape, LLC requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated according to Medscape policies. Others involved in the planning of this activity have no relevant financial relationships.
This activity was planned by and for the healthcare team, and learners will receive 0.25 Interprofessional Continuing Education (IPCE) credit for learning and change.
Medscape, LLC designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.25 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
Awarded 0.25 contact hour(s) of nursing continuing professional development for RNs and APNs; 0.00 contact hours are in the area of pharmacology.
Medscape designates this continuing education activity for 0.25 contact hour(s) (0.025 CEUs) (Universal Activity Number: JA0007105-0000-22-267-H01-P).
Medscape, LLC has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.25 AAPA Category 1 CME credits. Approval is valid until 8/5/2023. PAs should only claim credit commensurate with the extent of their participation.
For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]
There are no fees for participating in or receiving credit for this online educational activity. For information on applicability
and acceptance of
continuing education credit for this activity, please consult your professional licensing board.
This activity is designed to be completed within the time designated on the title page; physicians should claim only those
credits that reflect the
time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the
valid credit period that
is noted on the title page. To receive
AMA PRA Category 1 Credit™, you must receive a minimum score of 75% on the post-test.
Follow these steps to earn CME/CE credit*:
You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it.
Credits will be tallied in
your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as
the certificates from the
CME/CE Tracker.
*The credit that you receive is based on your user profile.
CME / ABIM MOC / CE Released: 8/5/2022
Valid for credit through: 8/5/2023
processing....
Allergic disorders including atopic dermatitis and other dermatological diseases, rhino-conjunctivitis, asthma, food, and drug allergies are common in children, with increasing prevalence especially in highly developed countries. These may cause physical discomfort and mental and behavioral problems.
Attention-deficit/hyperactivity disorder (ADHD), characterized by inattention and hyperactivity, affects 9% to 12% of the US population. ASD is characterized by deficits in social interaction and language communication, with US prevalence of approximately 2.47%.
Young children with allergies may be more likely to develop ADHD and autism spectrum disorder (ASD) by the time they are 18 years old, according to a large retrospective study.[1]
"[O]ur study provides strong evidence for the association between allergic disorders in early childhood and the development of ADHD," Shay Nemet, MD, from the Kaplan Medical Center in Rehovot, Israel, and colleagues write in Pediatric Allergy and Immunology. "The risk of those children to develop ASD was less significant."
The researchers analyzed data from 117,022 consecutive children diagnosed with at least 1 allergic disorder (asthma, conjunctivitis, rhinitis, drug, food, or skin allergy) and 116,968 children without allergies in the Clalit Health Services pediatric database. The children had been treated from 2000 to 2018; the mean follow-up period was 11 years.
The children who were diagnosed with 1 or more allergies (mean age, 4.5 years) were significantly more likely to develop ADHD (odds ratio [OR], 2.45; 95% confidence interval [CI], 2.39-2.51), ASD (OR, 1.17; 95% CI, 1.08-1.27), or both ADHD and ASD (OR, 1.56; 95% CI, 1.35-1.79) than were the control children who did not have allergies.
Children diagnosed with rhinitis (OR, 3.96; 95% CI, 3.80-4.12) and conjunctivitis (OR, 3.63; 95% CI, 3.53-3.74) were the most likely to develop ADHD.
Allergy Correlation With ADHD and ASDCy B. Nadler, PhD, a clinical psychologist and the director of Autism Services at Children's Mercy Kansas City, in Missouri, told Medscape Medical News that children and adults with neurodevelopmental differences are also more likely to have other health problems.
"Clinicians practicing in subspecialties such as allergy and immunology may have opportunities to help psychologists identify developmental and behavioral concerns early in childhood," he added.
"Studies like this can't be accomplished without large healthcare databases, but this approach has drawbacks, too," Dr Nadler said in an email. "Without more information about these patients' co-occurring medical and behavioral conditions, we are almost certainly missing important contributors to the observed associations."
Dr Nadler, who was not involved in the study, noted that in the multivariable analysis that controlled for age at study entry, sex, and number of annual visits, the link between allergy and ASD diagnosis was not significant.
"It is important to remember not to interpret these study results as causal," he added.
Desha M. Jordan, MD, an assistant professor of pediatrics at UPMC Children's Hospital of Pittsburgh, Pennsylvania, called the study "an interesting new area that has been speculated about for some time," and "one of the first I have seen with statistically significant correlations found between ADHD, ASD, and allergic conditions."
More Questions for Future StudiesHealthcare providers need to understand the potential sequelae of allergic conditions so that they can manage their patients appropriately, she advised.
Although symptoms and diagnoses were confirmed for all patients, the study's retrospective design and the possibility of recall bias were limitations, said Dr Jordan in an email. She also was not involved in the study.
"For example, the family of a child diagnosed with ADHD or ASD may have been more mindful of anything out of the norm in that child's past, while the family of a child without these conditions may not have recalled allergic symptoms as important," she explained.
Another question that arises is whether some patients were treated and managed well while others were not, and whether this disparity in care affected the development or severity of ADHD or ASD, she added.
"Is a patient with a well-controlled allergic condition less likely to develop ADHD or ASD than a patient with an uncontrolled allergic condition? Does a well-controlled patient ever return to the same probability of getting ADHD or ASD as a nonallergic patient?
"While this study expands our understanding of these conditions and their interrelationships, it also brings up many additional questions and opens a new segment of research," Dr Jordan said. "More studies in this area are necessary to confirm the findings of this paper."
The study was partially funded by the Israel Ambulatory Pediatric Association. The authors, Dr Nadler, and Dr Jordan have disclosed no relevant financial relationships.
Pediatr Allergy Immunol. Published online June 17, 2022.